Global Peptide Therapeutics Market – Global Industry Insights
Peptide are selective efficacious signaling molecules, which bind to specific cell surface receptors such as G Protein-Coupled Receptors (GPCRs) or ion channels, where they trigger intracellular effects. More than 7000 naturally occurring peptides have been identified, which have role in human physiology including functions such as neurotransmitters, hormones, growth factors, ion channel ligands, and anti-infective. Peptides are efficient precursors in designing of novel therapeutics, owing to their specificity, safety, tolerability intrinsic properties and its ability to provide expected results in humans. According to the Bioorganic & Medicinal Chemistry Journal, June 2018, around 60 peptide drugs are approved in the U.S. and in other major markets, such as Europe, and Japan.
Furthermore, peptides have low production complexity as compared to protein-based biopharmaceuticals, which lowers the production cost. Furthermore, peptides have wide range of applications in medicine, biotechnology, and therapeutics peptide research. Low production cost and increasing clinical applications are expected to drive growth of the peptide therapeutics market over the forecast period. Peptide therapeutics market size is forecasted to grow in coming years as peptide based therapeutics has already showed lucrative revenue opportunity to key manufactures, in the past years. For instance, according to the Drug Discovery Today Journal: January 2015, data findings, peptide-based medicine: Lupron from Abbott Laboratories for the treatment of prostate cancer and among others, achieved global sales of more than US$ 2.3 billion in 2011. Moreover, Lantus from Sanofi reached sales of US$ 7.9 billion in 2013.
The global peptide therapeutics market size was valued at US$ 22,071.5 Mn in 2017 and is expected to witness a CAGR of 9.1% over the forecast period (2018 – 2026).
Current Development Status of Therapeutic Peptides
Source: Bioorganic & Medicinal Chemistry Journal (June 2018)
Increasing Research and Development (R&D) Activities in the Field of Peptide Therapeutics is Expected to Drive Peptide Therapeutics Market Growth
Increasing Research and Development (R&D) activities in the field of peptide therapeutics and regulatory approval to peptide derived drugs or products shows lucrative trend in the peptide therapeutics market. For instance, according to the Drug Discovery Today Journal data findings, in 2015, more than 60 U.S. Food and Drug Administration (FDA) approved peptide medicines are available in market with around 140 peptide drugs in clinical trials and more than 500 therapeutic peptides in preclinical development. Moreover, peptide therapeutics market is projected to witness significant growth over the forecasted period, owing to the increase in the development of novel peptide drugs. Glucagon-like peptide-1 (GPL-1) agonists, one of the novel peptide drug class commonly used indicated for the treatment of type 2 diabetes mellitus (T2DM).
Increasing prevalence of cancer and diabetes among global population is expected to drive the growth of market. Moreover, increasing prevalence of obesity, type 2 diabetes mellitus (T2DM), rising mortality, and increasing demand for replacement of chemotherapy treatment is expected to drive growth of the peptide therapeutics market during the forecast period. For instance, according to the Cancer Atlas, 2017, an estimated 14.1 million new cancer cases were reported in 2012. According to the National Library of Medicine, 2016, number of people suffering from diabetes is estimated to be 56 million in European region with an overall estimated prevalence of 8.5%, in the same year. In addition to this, India, China and other East and Central Asian countries accounted for nearly half of world’s cancer cases and deaths in 2017. Furthermore, according to the same source, around 19.3 million population is estimated to suffer from cancer and around 11.4 million patients are estimated to die due to cancer by 2025 in emerging economies.
Furthermore, with the increasing prevalence of cancer, awareness among population is also increasing regarding early detection and treatment of cancer is expected to drive growth of the North America peptide therapeutics market. According to American Cancer Society data findings in 2012, North America accounted for high incidence rate of cancer in children as compared to any other region worldwide. Moreover, according to the same source, in 2012, North America accounted for 13.1% of total estimated cases of cancer worldwide. Furthermore, increasing incidence of diabetes mellitus worldwide is expected to drive the growth of the market. For instance, according to the World Health Organization (WHO), 2016, an estimated 422 million adults are suffering from diabetes. The major spike in incidence of type 2 diabetes over the last decade (2006-2016) is mainly attributed to high prevalence of obesity.
Moreover, early diagnosis of cancer increases the survival rate and reduces cancer mortality rate. For instance, in February 2017, World Health Organization (WHO), proposed new guidelines to improve survival rate of people suffering from cancer by ensuring that health service providers are focused on early diagnosis and treatment of disease. WHO proposed three steps to early diagnosis, which include improved public awareness of different cancer symptoms, invest in strengthening and equipping health services and training, and ensuring people living with cancer can access safe and effective treatment. Cancer Research UK organized Early Diagnosis Research Conference in February 2017, to share and discuss latest developments in early diagnosis research.
Moreover, manufacturers of pharmaceutical industry are now focusing on the development of drugs for rare disease and orphan drug, which is expected to extend the market size of peptide therapeutics, in near future. For instance, teduglutide, a GLP-2 receptor 2 agonist indicated for treatment of short bowel syndrome and pasireotide, a somatostatin receptor agonist indicated for the treatment of Cushing's syndrome.
Peptide drugs are usually administered through injections on a daily basis during long-term treatment, which is considered to be a drawback. As, oral administration involves high patience compliance and acceptance. But, low oral bioavailability of peptide drugs and poor penetration of the intestinal mucosa is hindering the growth of the peptide therapeutics market. Presently, many researches are going to overcome the challenge of absorption of peptide drugs among patients.
Key players operating in peptide therapeutics market include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Co. Ltd., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Encycle Therapeutics, Inc., CirclePharma, Inc., Pfizer Inc., Novartis AG, PeptiDream Inc., and Amgen Inc.
Peptide therapeutics continue to expands its application by broaden molecular diversity and by engineering enhanced pharmaceutical properties. Research continues to expand the potential range of peptide-based pharmaceuticals to focus on treatment targets. However, large number of peptide targets shown in its early-stage of clinical trials or in preclinical models of disease, such as a melanocortin 4 receptor (MC4R) agonist, may reduce the body weight of patients with genetic obesity syndromes.
Furthermore, increasing development are in progress to extend the half-life period of peptide drugs; to improve the oral bioavailability of peptide therapeutics and to enhance the Central Nervous System (CNS) availability of peptide drugs through nanoparticle delivery in the indications such as Alzheimer’s disease and stroke.
Market players are engaged in developing novel and innovative peptide therapeutics drugs in order to offer tailored solution to target patient by increasing biocompatibility and potent therapeutic effects. Increasing prevalence of cancer and diabetes mellitus is projected to drive growth of the peptide therapeutics market over the forecast period. Also, clinical development in the field of peptide reflects it as an effective tool for molecular pharmacology.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 26 market data tables and 45 figures on "Peptide Therapeutics Market - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.